PDCD1 and neoplasm: Subsequently, subcutaneous LLC tumor models were constructed using C57BL/6J mice to investigate the antitumor efficacy of QRHXF and its enhanced therapeutic efficacy when combined with anti-PD-1 immunotherapy for NSCLC (Fig. 1A).